Dalbavancin / Oritavancin / Telavancin
Dalbavancin, oritavancin, and telavancin are three distinct lipoglycopeptide antibacterials. They are a comparison category, not interchangeable names for one peptide.
At a glance
- Evidence stage
- Approved use
- Regulatory status
- US-approved products have specific bacterial-infection indications. Telavancin additionally has restricted hospital-acquired pneumonia labeling; approval is product-specific.
- Research context
- Dalbavancin, oritavancin, and telavancin are three distinct lipoglycopeptide antibacterials. They are a comparison category, not interchangeable names for one peptide.
What this is
- Dalbavancin, oritavancin, and telavancin are three distinct lipoglycopeptide antibacterials. They are a comparison category, not interchangeable names for one peptide.
What this isn't
- A recommendation to use, prepare, combine, or administer a product
- Evidence that a related molecule or a differently formulated product has the same effects
Key terms
Dalbavancin, oritavancin, and telavancin are three distinct lipoglycopeptide antibacterials. They are a comparison category, not interchangeable names for one peptide.
These antibacterial medicines act against susceptible Gram-positive bacteria through effects on cell-wall processes, with additional membrane effects for some members. Their long or distinctive pharmacology does not make them general immune enhancers. The individual labels define eligible organisms and infection sites; evidence for one member cannot automatically support another. Product label.
Evidence limits
How to read the evidence
Bloodstream-infection research should not be confused with the skin-infection indication in the dalbavancin label. The DOTS population had already responded to initial treatment. Neither that study nor a shared antibiotic class supports unsupervised substitution, treatment of viral illness, or use for nonspecific inflammation. Product-specific scope.
Sources appraised 2026-10-28. Educational information; not medical advice. Study findings apply to the populations, preparations and outcomes described.
External sources and citations
- Dalbavancin — product label (DailyMed; one member of this group)
- Dalbavancin for Treatment of Staphylococcus aureus Bacteremia: The DOTS Randomized Clinical Trial.
- Oritavancin (ORBACTIV) — product label
- Telavancin (VIBATIV) — FDA prescribing information, 2020
- FDA application ANDA219604 — approval and marketing records
Related peptides
Other published briefs in the same research family. Educational references only - not treatment recommendations.
5-Amino-1MQ
When a laboratory value changes but patient outcomes remain uncertain.
Open resourcePeptide brief5-Amino-1MQ / SLU-PP-332
Why the same acronym can refer to different molecules, salts, fragments, or blends.
Open resourcePeptide briefAbaloparatide
How abaloparatide fits into peptide therapeutics, osteoporosis care, and evidence-based bone health.
Open resourcePeptide briefAcetyl hexapeptide-8
Acetyl hexapeptide-8, also called Argireline, is a synthetic cosmetic peptide studied for the appearance of facial lines. Older publications may call the same ingredient acetyl hexapeptide-3.
Open resourcePeptide briefAcetyl octapeptide-3
Acetyl octapeptide-3 is a cosmetic peptide included in products marketed for facial expression lines. Evidence for a delivery system or mixture must be distinguished from evidence for this ingredient alone.
Open resourcePeptide briefAcetyl tetrapeptide-5
Acetyl tetrapeptide-5 is a cosmetic ingredient commonly associated with eye-area products. Laboratory activity is not the same as demonstrated reduction of under-eye puffiness in people.
Open resourceLearn the research basics
Foundational literacy pieces that help interpret evidence stage, product identity, and study design.
How to read a peptide study without overclaiming
A practical guide to research stage, controls, endpoints, uncertainty, and applicability.
Open resourceLiteracyWhy a biological mechanism is not a treatment promise
A practical explanation of why plausible pathways still need meaningful human-outcome evidence.
Open resourceLiteracyPeptide naming, aliases, and product identity
Why the same acronym can refer to different molecules, salts, fragments, or blends.
Open resourceLiteracyFrom preclinical finding to human evidence
Why a compelling cell or animal result is the beginning of a question, not the end of it.
Open resourceLiteracyFDA approved, compounded, and unapproved are not synonyms
A plain-language map of product categories that are often blurred in peptide discussions.
Open resourceLiteracyUnderstanding surrogate endpoints in peptide research
When a laboratory value changes but patient outcomes remain uncertain.
Open resourceWatch & read
Same-family videos and articles from the Articles & Media channel. Educational references only.
Preparing for a peptide conversation with a clinician
A neutral question list for discussing goals, evidence, product status, and uncertainty.
Open resourceArticleA clinical-trial record is not proof that a peptide works
What a trial registry can tell you, what it cannot, and how to avoid overreading a study status.
Open resourceArticleAn ingredient name is not a complete product
Why matching a molecule name does not establish sameness in approval, formulation, quality, or evidence.
Open resourceRelated articles
Same-family articles from the published library. Educational references only - not treatment recommendations.
Preparing for a peptide conversation with a clinician
A neutral question list for discussing goals, evidence, product status, and uncertainty.
Open resourceArticleA clinical-trial record is not proof that a peptide works
What a trial registry can tell you, what it cannot, and how to avoid overreading a study status.
Open resourceArticleAn ingredient name is not a complete product
Why matching a molecule name does not establish sameness in approval, formulation, quality, or evidence.
Open resource